Frontlight ResearchEarly access
WithdrawnEarly phase 1
γδ T Cell Therapy for Relapse Prevention in High-Risk AML Post-Transplant
Key facts
- Who runs it
- Guangzhou Bio-gene Technology Co., Ltd
- Trial code
- Status
- Withdrawn
- Phase
- Early phase 1
- Started
- 1 Sept 2025
- Expected to end
- 30 May 2028
- Type of study
- Interventional, 2 groups
- Treatments tested
- Gamma-Delta T cell injection
- Standard prophylactic treatment
- Record updated
- 28 May 2026
- Why it stopped
- Due to corporate strategic adjustment.
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 20 criteriaShow less
Who can take part
- Patients voluntarily sign informed consent and are expected to complete the follow-up examination and treatment of the study procedures
- Age 18-65 years old (including cut-off value), gender is not limited
- AML patients have one of the high-risk factors for recurrence after allogeneic hematopoietic stem cell transplantation
- AML patients need to meet 30±5 days after the end of allogeneic transplant therapy
- The patient has recovered from the toxicity of the prior treatment, i.e., CTCAE toxicity grade < 2 (unless the abnormality is related to the tumor or is stable as judged by the investigator and has little impact on safety or efficacy)
- ECOG performance status score of 0-3 points and expected survival greater than 3 months
- Have appropriate organ function:; Alanine aminotransferase (ALT) ≤3 times the upper limit of normal (ULN); Aspartate aminotransferase (AST) ≤ 3 times ULN; Total bilirubin ≤1.5 times ULN; Serum creatinine ≤1.5 times ULN or creatinine clearance ≥ 60 mL/min; Hemoglobin ≥ 50g/L (must not have received transfusion support within 7 days prior to laboratory tests); Room oxygen saturation ≥92%; Left ventricular ejection fraction (LVEF) ≥ 45%, echocardiography confirmed no pericardial effusion, no clinically significant ECG findings; Without clinically significant pleural effusion
Who cannot take part
- Other malignant tumors within 3 years prior to screening, except for adequately treated carcinoma in situ of the cervix, papillary carcinoma of the thyroid, basal cell or squamous epithelial cell skin cancer, localized prostate cancer after radical resection, and ductal carcinoma in situ after radical resection
- Patients who are using (or willing to use) other maintenance therapy drugs after hematopoietic stem cell transplantation and have proven that this maintenance therapy drug is not conducive to the persistence of γδ T cells in vivo
- Those who have participated in other clinical studies within 1 month before screening and have not interfered with the safety and efficacy of this study drug as assessed by the investigator are allowed to be included in the study, such as non-interventional observational studies
- Patients have a severe allergic history
- The patient has severe heart disease
- The patient has severe respiratory system disease
- Active neurological autoimmune or inflammatory diseases, amyotrophic lateral sclerosis (ALS), and clinically significant active cerebrovascular disease
- Patients with severe mental illness
- Alcoholics or those with a history of drug abuse
- Clinically significant active cerebrovascular disease
- Those with grade III~IV acute GVHD or extensive chronic GVHD
- Pregnant or lactating women, and female subjects who plan to become pregnant within 1 year after cell reinfusion or male subjects whose partners plan to become pregnant within 1 year after their cell reinfusion
- Any unsuitable to participate in this trial judged by the investigator
About the trial
What the trial wants to find out
This is a prospective, double-arm, single-center, randomized controlled single-blind clinical study
The 2 groups in the trial
- Gamma-Delta T cell injectionTreatment being tested
Experimental group: Received γδT infusion after high-risk AML allogene transplantation standard prophylactic treatment.
- Standard prophylactic treatmentOther group
Control group: High-risk AML received only standard prophylactic treatment after allogeneic transplantation
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Clinical Study on the Safety and Efficacy of γδ T Cells in Preventing Relapse After Allogeneic Transplantation in High-risk Acute Myeloid Leukemia Patients
- Record updated
- 28 May 2026